November 01, 2017
Biophytis completes a € 7,5 M capital increase to help accelerate pipeline programs in orphan pediatric diseases. Read the press release
October 30, 2017
Biophytis has FDA Approval to initiate SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia. Read the Press Release
October 27, 2017
Biophytis appoints Professor Thomas Voit to Scientific Advisory Board to help accelerate pipeline programs in orphan pediatric diseases. Read the Press Release
October 26, 2017
Half-Year Financial Report as of June 30, 2017. Read the press release
October 11, 2017
Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release
October 10, 2017
Interview of Stanislas Veillet, CEO of Biophytis for the European Large & Midcap event 2017 with Didier Testot, journalist on the Web tv www.labourseetlavie.com
September 2, 2017
Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia. Read the Press Release
September 20, 2017
Biophytis to participate in upcoming industry and investors conferences. Read the Press Release
September 11, 2017
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release
September 08, 2017
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy . Read the Press Release